We are live on ! Find out more
DMTK

DermTech, Inc. Common Stock

Delisted

DMTK was delisted on the 26th of June, 2024.

176 hedge funds and large institutions have $845M invested in DermTech, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 76 increasing their positions, 30 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 30

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

4% more funds holding

Funds holding: 169176 (+7)

7% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $18.1M

17% less capital invested

Capital invested by funds: $1.01B → $845M (-$169M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
176
Holders Change
+7
Holders Change %
+4.14%
% of All Funds
3.06%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
47
Increased
76
Reduced
30
Closed
40
Calls
$16.9M
Puts
$18.1M
Net Calls
-$1.25M
Net Calls Change
-$8.05M
Name Holding Trade Value Shares
Change
Change in
Stake
RI
1
RTW Investments
New York
$130M
CC
2
Casdin Capital
New York
$72.5M
BlackRock
3
BlackRock
New York
$68.2M +$27.8M +677,518 +70%
State Street
4
State Street
Massachusetts
$64.7M +$19.3M +468,875 +43%
Vanguard Group
5
Vanguard Group
Pennsylvania
$51.1M +$11.4M +278,443 +29%
ICM
6
ISZO Capital Management
New York
$45.3M -$30.1M -732,140 -40%
Federated Hermes
7
Federated Hermes
Pennsylvania
$44.6M -$843K -20,511 -2%
Victory Capital Management
8
Victory Capital Management
Texas
$30.7M -$1.59M -38,805 -5%
OIM
9
Oracle Investment Management
Connecticut
$27.3M -$2.37M -57,700 -8%
Ameriprise
10
Ameriprise
Minnesota
$24.1M -$4.83M -117,589 -17%
CAM
11
Cormorant Asset Management
Massachusetts
$18.7M -$14.4M -350,000 -44%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$17.1M +$4.78M +116,429 +39%
FAM
13
Fred Alger Management
New York
$16.4M +$8.74M +212,864 +117%
CG
14
Carmignac Gestion
France
$15.9M +$3.28M +79,860 +26%
NIP
15
Nicholas Investment Partners
California
$15.2M -$1.26M -30,573 -8%
Northern Trust
16
Northern Trust
Illinois
$10.8M +$4.22M +102,777 +65%
ITP
17
Iron Triangle Partners
Connecticut
$10.4M
Two Sigma Investments
18
Two Sigma Investments
New York
$10.3M +$10.2M +248,182 New
KCM
19
Kornitzer Capital Management
Kansas
$8.99M +$1.8M +43,915 +25%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$8.42M -$2.03M -49,378 -20%
Morgan Stanley
21
Morgan Stanley
New York
$7.55M +$1.87M +45,641 +34%
TCM
22
Tygh Capital Management
Oregon
$6.67M +$2.48M +60,424 +60%
EP
23
EPIQ Partners
Minnesota
$6.31M +$201K +4,895 +3%
1WCM
24
12 West Capital Management
New York
$6.24M +$6.16M +150,000 New
LCG
25
Lisanti Capital Growth
New York
$5.66M +$870K +21,190 +18%

DMTK Hedge Fund Activity: Q2 2021 in Review

176 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in DermTech, Inc. Common Stock (DMTK) for Q2 2021, worth a combined $845M — down 17% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new DMTK positions and 40 closed out — a net gain of 7 holders — while 76 added to existing stakes and 30 trimmed.

The largest buyer was BlackRock, adding an estimated $27.8M. The largest seller was ISZO Capital Management, cutting an estimated $30.1M.

  • 176 institutional investors held DermTech, Inc. Common Stock (DMTK) as of Q2 2021, up from 169 in Q1 2021.
  • Funds reported $845M of DermTech, Inc. Common Stock stock for Q2 2021, down 17% quarter-over-quarter.
  • 47 funds opened new DermTech, Inc. Common Stock positions in Q2 2021 and 40 closed out, a net change of +7 holders.
  • The largest DermTech, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $27.8M added.
  • The largest DermTech, Inc. Common Stock seller in Q2 2021 was ISZO Capital Management, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2021.